ClinicalTrials.gg
Active, not recruitingNCT07441707Updated Oct 1, 2026

A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

A Phase 1 interventional study of Tovorafenib in Low-grade Glioma, sponsored by Ipsen. Active, not recruiting at 6 sites in Japan. Open to participants aged 6 Months to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Ipsen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
6 Months to 25 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate safety and the way the body absorbs, distributes and gets rid of the study drug tovorafenib in the body in Japanese children, adolescents and young adults with specific brain tumours. This includes how the drug is absorbed, distributed and eliminated from the body (called pharmacokinetics). The study will also test how well the drug works to shrink brain tumours.

In this study, all participants will receive tovorafenib orally once weekly.

There will be four periods in this study:

  1. Screening period (up to 4 weeks): Participants will be evaluated to determine if they can take part in the study, requiring at least one visit to the study centre.
  2. Treatment period (up to 24 months): All eligible participants will receive tovorafenib.

    This requires five visits for the first 2 months (Cycle 1 and Cycle 2) followed by one visit every month (at the start of each treatment cycle). Participants will receive the first oral dose of tovorafenib on Day 1 of Cycle 1 at the study clinic. After Day 1, participants will need to take tovorafenib once weekly on Day 8, Day 15 and Day 22. Participants will be required to come to the study clinic in person at least five times for Cycle 1 and Cycle 2.

    In addition, participants will have one remote visit (telephone call) during Cycle 1. After Cycle 2, only one in-person clinic visit is required at the start of each treatment cycle. A participant will stop treatment if their disease gets worse, if treatment has a harmful effect, or if they do not want to take part in the study anymore.

  3. End-of-Treatment Safety Follow-Up (30 days): Participants will have a clinic visit 30 days after stopping treatment to check their health.
  4. Long-Term Follow-Up (up to 2 years): Participants will be monitored every 3 months unless they start a new anti-cancer treatment or leave the study.

During the study, participants will undergo various health measurements and observations, including blood sampling and urine collections. Each participant will be in this study for up to approximately 4 years. Tovorafenib will be provided to participants who tolerate it for as long as their disease does not progress.

Once tovorafenib becomes approved and commercially available in Japan, participants may transition to the commercial drug for continued treatment.

A participant may withdraw consent to participate at any time.

02

Conditions studied

  • Low-grade Glioma

Keywords

  • BRAF-altered Recurrent Low-grade Glioma
  • Progressive Low-grade Glioma
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 6 months to 25 years of age, inclusive, with at least two generations of Japanese ancestry at the time of signing the informed assent/consent.
  • Participants must have or progressive low-grade glioma with a documented known activating BRAF alteration, including BRAF V600 mutations and KIAA1549:BRAF fusions, as identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments-certified or other similarly certified laboratories.
  • Participants must have histopathologic verification of at either original diagnosis or relapse.
  • Participants must have received at least one line of prior systemic therapy and have documented evidence of radiographic progression.
  • Participants must have at least one evaluable and/or (imaging must be performed within 28 days of initiation of treatment) as defined by Response Assessment in Neuro-Oncology-high grade glioma criteria (T1 weighted lesion that can be reproducibly measured in at least two dimensions of at least 10 mm, visible on ≥2 axial slices that are preferably, at most, 5 mm apart with 0 mm skip).
  • Participants must have fully recovered from the acute toxic effects of all prior anticancer chemotherapy
  • Chronic toxicities from prior anticancer therapy must be stable and at National Cancer Institute (NCI) (CTCAE) Version 5.0 Grade ≤2; ongoing retinopathy must be ≤1.
  • Participants must have adequate hematologic, hepatic and renal function
  • Participants receiving for tumour-associated symptoms must be on a stable dose (e.g. no initial/loading dose, no increase or decrease) for 14 days prior to C1D1.
  • Participants must be able to swallow tablets or liquid or administer through gastric access via a feeding tube (12 Fr or greater).

Exclusion criteria

Exclusion Criteria

  • Participant's tumour has an additional previously known or expected to be activating molecular alteration(s) (e.g. histone mutation, isocitrate dehydrogenase 1 and 2 mutations, fibroblast growth factor receptor mutations or fusions, MYBL v-myb avian myeloblastosis viral oncogene homolog-like alterations, neurofibromatosis type-1 somatic or germline mutations).
  • Participant has symptoms of clinical progression without radiographically recurrent or radiographically progressive disease.
  • Participant has known or suspected diagnosis of neurofibromatosis type 1 via genetic testing or current diagnostic criteria.
  • Participant has history of any major disease (e.g. confirmed or suspected diagnosis of interstitial lung disease), other than the primary under study, that in the opinion of the investigator might interfere with safe protocol participation.
  • Participant has a history or current evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO), or ophthalmopathy present at baseline that would be considered a risk factor for CSR or RVO. Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor or strabismus) will NOT be considered significant abnormalities for the purposes of this study.
  • Participant has major surgery within 14 days (2 weeks) prior to Cycle 1 Day 1 (does not include central venous access, cyst fenestration or cyst drainage, or ventriculoperitoneal shunt placement or revision).
  • Participant has active cardiovascular disease, history of myocardial infarction, deep vein thrombosis/pulmonary embolism within 6 months prior to C1D1, ongoing cardiomyopathy or current prolonged corrected for heart rate by Fridericia's formula interval >470 milliseconds based on triplicate (ECG) average.
  • Participant has nausea and vomiting v5.0 Grade ≥2, malabsorption requiring supplementation or significant bowel or stomach resection that would preclude adequate absorption of tovorafenib.
  • Participant is neurologically unstable despite adequate treatment (e.g. uncontrolled seizures).
  • Concomitant medications that are strong inhibitors or inducers of CYP2C8 within 14 days before initiation of therapy. Concomitant medications that are substrates of breast cancer resistance protein (BCRP) with a narrow therapeutic index within 14 days before initiation of therapy.
  • Participant has any clinically significant skin toxicity at Screening that in the opinion of the investigator would increase risk of severe skin toxicity when using product.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Tovorafenib

    Tablet or powder for reconstitution / powder for oral suspension, administred once weekly

    Drug: Tovorafenib

Interventions

  • Tablet or powder for reconstitution / powder for oral suspension

    Also known as: Ojemda®

06

What researchers measure

Primary outcomes

  1. Percentage of participants experiencing Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)

    Time frame: From first dose until 30 days post-treatment

  2. Percentage of participants experiencing Serious Adverse Events (SAEs) and AESIs

    An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention.

    Time frame: Up to 4 years from first dose, including post-treatment monitoring

  3. Area under the plasma concentration-time curve from time zero to last measurable concentration (AUC₀-t) of tovorafenib following a single dose

    AUC₀-t represents the total drug exposure over time from administration until the last measurable concentration after a single dose of tovorafenib.

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  4. Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC₀-inf) of tovorafenib following a single dose

    AUC₀-inf estimates the total drug exposure from administration to infinite time, extrapolating beyond the last measurable concentration.

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  5. Maximum observed plasma concentration (Cmax) of tovorafenib following a single dose

    Cmax is the highest concentration of tovorafenib observed in plasma after a single dose

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  6. Time to maximum plasma concentration following a single dose (Tmax) of tovorafenib

    Tmax refers to the time point at which the maximum observed plasma concentration of tovorafenib is reached following a single dose

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  7. Terminal half-life (t½) of tovorafenib following a single dose

    Terminal half-life (t½) will be assessed following a single dose of tovorafenib.

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  8. Area under the plasma concentration-time curve over the dosing interval at steady-state (AUC₀-tau) of tovorafenib

    AUC₀-tau refers to the area under the plasma concentration-time curve over the dosing interval (tau) during steady-state conditions, representing total drug exposure per dosing cycle

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  9. Maximum plasma concentration at steady-state (CmaxSS) of tovorafenib

    CmaxSS refers to the maximum observed plasma concentration of tovorafenib measured during steady-state conditions, after repeated dosing when drug input and elimination have reached equilibrium.

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  10. Minimum plasma concentration at steady-state (CminSS) of tovorafenib

    CminSS refers to the lowest observed plasma concentration of tovorafenib during steady-state conditions, reflecting trough levels between doses.

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  11. Average Plasma Concentration at Steady-State (CavSS) of tovorafenib

    CavSS refers to the average plasma concentration of tovorafenib over the dosing interval during steady-state conditions, calculated from multiple time points

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

  12. Time to maximum plasma concentration at steady-state (TmaxSS) of tovorafenib

    TmaxSS refers to the time point at which the maximum plasma concentration of tovorafenib is observed during steady-state conditions

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 8 (each cycle is 28 days)

Secondary outcomes

  1. Change in total tumor volume over time

    Assessment based on MRI imaging data to evaluate tumor volume and its evolution during treatment.

    Time frame: Every 12 weeks from Cycle 1 Day 1 up to end of treatment (approximately 24 months).

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jul 2030, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Mar 2, 2026
StartActual
Mar 10, 2026
Primary completionEst.
Jul 31, 2030
CompletionEst.
Jul 31, 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07441707
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Mar 10, 2026
Primary completion
Jul 31, 2030 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovorafenib

Start the discussion